Ultimovacs cancer vaccine fails in Phase II trial for head and neck cancer
The combination treatment of Ultimovacs’ cancer vaccine UV1 and MSD’s Keytruda failed to meet primary and secondary endpoints in a Phase II trial.
06 August 2024
06 August 2024
The combination treatment of Ultimovacs’ cancer vaccine UV1 and MSD’s Keytruda failed to meet primary and secondary endpoints in a Phase II trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.